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Abstract: Currently used Brucella vaccines, Brucella abortus strain 19 and RB51, comprises of
live attenuated Brucella strains and prevent infection in animals. However, these vaccines pose
potential risks to recipient animals such as attenuation reversal and virulence in susceptible hosts
on administration. In this context, recombinant subunit vaccines emerge as a safe and competent
alternative in combating the disease. In this study, we formulated a divalent recombinant vaccine
consisting of Omp25 and L7/L12 of B. abortus and evaluated vaccine potential individually as
well as in combination. Sera obtained from divalent vaccine (Omp25+L7/L12) immunized mice
group exhibited enhanced IgG titers against both components and indicated specificity upon
immunoblotting reiterating its authenticity. Further, the IgG1/IgG2a ratio obtained against each
antigen predicted a predominant Th2 immune response in the Omp25+L7/L12 immunized mice group.
Upon infection with virulent B. abortus 544, Omp25+L7/L12 infected mice exhibited superior Log10
protection compared to individual vaccines. Consequently, this study recommends that simultaneous
immunization of Omp25 and L7/L12 as a divalent vaccine complements and triggers a Th2 mediated
immune response in mice competent of providing protection against brucellosis.
Keywords: Recombinant vaccine; divalent vaccine; brucellosis; Omp25; L7/L12; Brucella abortus 544

1. Introduction
Brucellosis, one of the major bacterial zoonoses across the globe, is caused by members of the
Brucella genus, (B. abortus, B. melitensis, B. suis and B. canis). It is still considered one of the seven
"neglected zoonoses" worldwide, in spite of a huge public health burden in many countries with
low income [1]. The transmission of brucellosis in humans occurs through coincidental exposure to
pathogenic bacterium from infected animals or animal products [2–6]. Domestic animals affected by
brucellosis are more prone to abortions whereas human brucellosis leads to debilitating symptoms
such as recurrent fevers, spondylitis, joint pains, and osteomyelitis [7–9]. The successful vaccines
available commercially against brucellosis are Strain 19 and RB51 [10]. Strain 19 is an attenuated
B. abortus strain with smooth morphology that has the capability to induce antibody responses and
protect cattle against brucellosis. B. abortus RB51 is a rifampicin-resistant strain with rough morphology
which provides protection against infection and abortion [11]. But there are several disadvantages
associated with these vaccines such as occurrence of abortions in pregnant cows, restriction on age
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of vaccination, and reversion of vaccine strain back to pathogenic strain upon administration [12].
Further, antibodies are directed majorly against the lipopolysaccharide O-side chain during natural
infection or S19 immunization which causes obstruction during a brucellosis diagnostic test. Therefore,
development of an effective and safe vaccine is required.
In this context, recombinant protein-based subunit vaccines have an advantage over traditional
live-attenuated vaccines as being protective and safe for human administration [13–15]. Recombinant
subunit vaccines rely on specific parts of the pathogenic microorganism such as proteins or
capsular polysaccharides containing protective epitopes to result in a protective immune response.
Since these vaccines cannot replicate in the host, they are not pathogenic on administration [16].
Numerous intracellular components and surface proteins from bacteria have been researched as
potential protective antigens against Brucella infection, such as L7/L12 [17], Omp19, Omp31 [18],
BLS [19], BP26 [15] and Omp25 [20,21], and some have shown to be effective in providing significant
protection against Brucella infection [15,17,20,21]. Although recombinant subunit vaccines offer
no residual virulence but these require administration of multiple boosters along with providing
lower levels of protection [22]. Further, when these Brucella protective antigens were administered
in combination, the induced immune responses were superior in clearing intracellular Brucella as
compared to their univalent counterpart [14,15,18,23–27]. Earlier studies have suggested that Omp25
and L7/L12 can serve as efficient protective antigens by inducing strong humoral and cellular immune
response [17,20,28]. Outer membrane protein 25 (Omp25) of Brucella species has been identified as
a potential antigen [20,28] capable of inhibiting TNF-α production [21]. Importantly, omp25 gene is
highly conserved in multiple Brucella species, strains, and biovars [8]. In addition, L7/L12 is a conserved
protein which is found to be immunogenic and a stimulant of Th1 type CD4+ cellular response in
mice [17], making both these antigens relevant as components for divalent vaccine formulation against
brucellosis. Further, many protective antigens from Brucella have been classified as specific and novel
diagnostic target as compared to LPS based conventional tests [29,30].
Aluminum hydroxide (Alum) has been validated as an economical and safe adjuvant by U.S.
Food and Drug administration for veterinary and human use. Aluminum salts form a short-term depot
at the site of injection and slowly release antigen to the body’s immune system [31,32]. In this study,
we co-immunized Omp25 and L7/L12 of Brucella abortus using alum as an adjuvant. Elicited antibody
titers and antibody subtype profile were analyzed when administered as a divalent vaccine candidate in
BALB/c mice. Further, the protective efficacy of individual proteins and the divalent vaccine candidate
against virulent B. abortus 544 challenge were determined.
2. Results
2.1. Expression and Purification of Recombinant Proteins rOmp25 and rL7/L12
The recombinant proteins rOmp25 and rL7/L12 were expressed in E. coli C43 cells and E. coli
BL21 (DE3) cells respectively and purified using Ni-NTA chromatography. Further, the size of
the expressed recombinant proteins was verified using 12% SDS-PAGE electrophoresis (Figure 1a).
The immunoreactivity of purified proteins was confirmed by immunoblotting using (anti-Omp25+
L7/L12) mice serum signifying that serum from mice immunized with Omp25+L7/L12 consisted of
antibodies specifically against its component proteins rOmp25 and rL7/L12 (Figure 1b).
Further, the virulence potential of rOmp25 and rL7/L12 was analyzed using bioinformatics analysis
using VirulentPred and VaxiJen. VirulentPred is a tool used for prediction of virulent protein sequences
in bacteria based on bi-layer cascade support vector machine (SVM) [33]. The SVM classifiers in
this tool were trained and optimized using individual protein sequence features such as their amino
acid and dipeptide composition along with position-specific iterated blast (PSI-BLAST). This tool
distinguishes virulent proteins from non-virulent bacterial proteins with an accuracy of 81.8% [33].
On the basis of VirulentPred, rOmp25 and rL7/L12 were concluded to be virulent with predicted scores
of 1.0411 and 0.2440, respectively (Figure 1c). In addition, we used the VaxiJen tool [34], which uses an
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alignment-independent approach for prediction of protective antigens. The antigen classification is
purely based on the physiochemical properties of proteins without applying sequence alignment [34],
and depends on auto cross covariance (ACC) transformation of protein sequences into uniform vectors
of amino acid properties. VaxiJen results categorized Omp25 and L7/L12 as vaccine antigens with
predicted scores of 0.7506 and 0.6442, respectively, at the threshold value of 0.4 (Figure 1d).

Figure 1. (a) Purification of rL7/L12 and rOmp25: SDS-PAGE gel stained with coomassie blue stain
showing purification of rL7/L12 and rOmp25 recombinant proteins corresponding to 17 KDa and
25 KDa, respectively. (b) Immunoblotting with polyclonal sera of mice immunized with divalent
vaccine (Omp25+L7/L12): The reactivity of purified proteins was confirmed by immunoblotting using
anti-Omp25+L7/L12 mice serum. Negative control (lane 1; E. coli BL21 (DE3) cells with pET28a
only), marker (lane 2) Precision Plus Protein™ Dual Color Standards, BIORAD #1610374, rOmp25
(lane 3), and rL7/L12 (lane 4). (c) Prediction of virulent proteins in a bacterium using VirulentPred:
The sequences for Brucella abortus protein, Omp25 and L7/L12, have been submitted as input and their
predicted scores have been calculated using VirulentPred software. (d) Prediction of vaccine antigens
using VaxiJen: The sequences for Brucella abortus protein, Omp25 and L7/L12, have been submitted as
input and the probability of these proteins being vaccine antigens has been predicted using VaxiJen.

2.2. Determination of IgG Antibody Titre upon Divalent Vaccine Immunization
To assess the levels of IgG antibody titer generated in each of the immunized mice groups,
sera was collected at day 28 and 42 post-priming and levels were estimated using Enzyme linked
immunosorbent assay (ELISA). Our results revealed that immunization with Omp25+L7/L12 supported
a robust anti-L7/L12 IgG response that was detectable at day 28 and remained stable until day 42.
At day 28, anti-L7/L12 antibodies were observed to be higher in Omp25+L7/L12 mice compared to
L7/L12 only immunized mice (p < 0.05; Figure 2a). At day 42, anti-L7/L12 levels were found to be similar
in both L7/L12 and Omp25+L7/L12 immunized mice (approximately 6 × 105 in both). Immunization
with divalent vaccine elicited a vigorous anti-Omp25 IgG response as well. Antibody levels were
observed to be similar in Omp25+L7/L12 and Omp25 only immunized mice at day 28 and day 42
(Figure 2b). Therefore, the antigen alone vaccinated group generated antibodies only against a single
antigen, whereas mice immunized with divalent vaccine (Omp25+L7/L12) produced antibodies against
both components (rOmp25 and rL7/L12) in a cumulative manner, indicating that co-immunization of
two proteins didn’t hinder the immune response and supported generation of antibodies against its
individual components.
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Figure 2. IgG antibody response elicited after immunization with L7/L12, Omp25, and divalent vaccine
(Omp25+L7/L12): The mice were immunized with proteins rOmp25, rL7/L12 and rOmp25+rL7/L12
followed by isolation of serum samples from tail veins on day 14, 28, and 42. Estimation of IgG antibody
end point titer was done through Enzyme linked immunosorbent assay (ELISA) and data is plotted as
(mean ± SD).

2.3. Evaluation of IgG Isotype Levels upon Divalent Vaccine Immunization
In order to predict the Th1/Th2 bias of immune response, the relative IgG isotypes levels
(IgG1, IgG2a and IgG2b) were analyzed in Omp25+L7/L12 immunized mice along with mice immunized
solely with L7/L12 and Omp25. In the case of anti-L7/L12 antibodies, IgG1 levels were found to be
significantly higher than IgG2a levels in the divalent vaccine as well as L7/L12 only immunized mice
group, indicating a Th2 biased immune response in both (Figure 3a). Similarly, in the case of anti-Omp25
antibody levels, IgG1 levels were found to be higher than IgG2a (IgG1/IgG2a = 1.86), suggesting a Th2
biased immune response in divalent vaccine immunized mice. Interestingly, levels of IgG2a and IgG2b
antibodies in Omp25+L7/L12 immunized mice were noteworthy (Figure 3b), predicting an elicitation
of Th1 immune response in divalent vaccine immunized mice as well.

Figure 3. IgG antibody isotypes (IgG1, IgG2a, and IgG2b) elicited after immunization with rL7/L12,
rOmp25, and divalent vaccine (Omp25+L7/L12): The recombinant B. abortus proteins rL7/L12, rOmp25,
and Omp25+ L7/L12 were immunized in mice and isolation of serum samples was done from tail veins
on day 42. Estimation of IgG isotype levels in serum of immunized mice was done through ELISA.
The antibodies used for ELISA were horseradish peroxidase (HRP) conjugated anti-mouse IgG1, IgG2a,
and IgG2b antibodies and data is plotted as (mean (OD450 ± SD)).
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2.4. Evaluation of Protective Efficacy Conferred by Divalent Vaccine Candidate against B. abortus 544 Challenge
The protective efficacy of the Omp25+L7/L12 vaccine candidate along with groups immunized
solely with Omp25 and L7/L12 was analyzed against B. abortus 544 infection. Two weeks after last
immunization, the immunized mice were challenged with virulent B. abortus 544 through intraperitoneal
route. The mice were sacrificed four weeks post-infection, and bacterial colony forming units (CFU)
were determined. As shown in Table 1, the level of log10 CFU per spleen at 28 days post-challenge with
B. abortus 544 was (4.820 ± 0.18) in Omp25+L7/L12 immunized mice. Consecutively, log10 protection
conferred by the Omp25+L7/L12 group was 1.98 at 28 day post-challenge as compared to (PBS + alum)
immunized mice indicating that the Omp25+L7/L12 vaccine candidate was effective at eliminating
pathogenic B. abortus 544 from a mice model. Mice immunized with Omp25 and L7/L12 alone exhibited
log10 units of protection as 1.46 and 1.75, respectively at 28 days post-challenge with B. abortus 544
as compared to (PBS + alum) immunized mice. Overall, upon analyzing the levels of protection of
the divalent vaccine candidate against B. abortus 544 challenge, it was found that Omp25+L7/L12
immunized mice exhibited efficacious log10 units of protection against B. abortus 544 challenge along
with its individual components, however S19 exhibited the maximum.
Table 1. Bacterial proliferation in the spleen of mice immunized with rOmp25, rL7/L12, divalent
vaccine candidate (Omp25+L7/L12) and control, using alum as adjuvant. The mice were infected with
B. abortus 544 through intraperitoneal route and the splenic bacterial load was determined by plating
dilutions of the splenocytes suspension on the tryptic soya agar plates followed by incubation at 37 ◦ C
in the presence of 5% CO2 for 48 h. Data is represented as mean ± S.D.
S. No

Vaccine Candidate

Log10 Spleen Bacillary Load
at Day 28 Post-Challenge
(Log10 CFU)

Log10 Units of
Protection at Day 28
Post-Challenge

1.

rOmp25

5.338 ± 0.75

1.46

2.

rL7/L12

5.05 ± 0.27

1.75

3.

Omp25+L7/L12

4.820 ± 0.18

1.98

4.

PBS

6.80 ± 0.58

–

5.

B. abortus S19

4.21 ± 0.31

2.59

3. Discussion
Brucellosis is still a major public health concern and endemic in many countries, mainly in the
Mediterranean region, eastern and western Africa, and parts of South and Central America. There is a
substantial requirement to control and eradicate this disease caused by the Brucella genus [4,5,7,35,36].
The current vaccines in use, Strain 19 and RB51 despite being popular are still far from ideal [12,37].
They prevent infection in animal but offer potential risks such as attenuation reversal and virulence in
susceptible hosts. In this context, subunit vaccines are better options as compared to live attenuated
vaccines, since they are safe and do not revert back to pathogenic strain upon administration [13–15].
Further, recombinant subunit vaccines protect against a given pathogen by activating humoral and
cellular arms of immunity based upon a specific antigen along with used adjuvant, which makes them
competent and useful in the vaccine field. There are certain proteins in Brucella species which can
provide significant protection against the disease and are conserved throughout, such as L7/L12 [17],
Omp19, Omp31 [18], BLS [19], BP26 [15], and Omp25 [20,21]. Among these, omp25 and l7/l12 genes in
Brucella species encode for Omp25 and L7/L12 immunodominant proteins respectively, and have the
potential to stimulate a strong humoral immune response along with providing protection against
Brucella infections in mice models [15,17,20,28]. Earlier studies have suggested that outer membrane
proteins from Brucella such as Omp25 [38], Omp10 [39], Omp19 [39], BP26 [40], Omp28 [41,42],
and Omp31 [30] can distinguish between Brucella-infected animals and non-infected ones in an efficient
and accurate way, withdrawing the false positive results in the field due to cross-reacting antibodies.
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Further multivalent subunit vaccine formulations possess the capability to generate a wide range of
immunogens that may result in better protection than their univalent counterpart [24–26]. In this
study, we evaluated humoral immune response and protective efficacy of a divalent vaccine candidate
consisting of rOmp25 and rL7/L12 against Brucella infection in mice. The foremost point to be explored
in this study was whether two components combined together in a divalent vaccine have the capability
to show a synergistic response and promote a heightened immune response, or if some kind of
competitive inhibition occurs among them? Aluminum hydroxide (Alum) is beneficial since it is
inexpensive and has been certified as the safest adjuvant for use by the United States Food and Drug
Administration [31,32,43]. Alum creates a depot effect at the site of injection, resulting in a slow
release of adsorbed antigens and an elevation in the immune response. The intraperitoneal route of
administration was chosen because it helps to quickly absorb antigens into the vasculature, which leads
to a rise of antigen drainage into the spleen and activation of immune cells circulating in the lymph
nodes [44].
The results in this study exhibited that humoral immune response was elevated in mice immunized
with the divalent vaccine Omp25+L7/L12 as compared to the control group (PBS + alum). The divalent
vaccine (Omp25+L7/L12) was found immunogenic with high IgG levels against both of its components,
rOmp25 and rL7/L12 (Figure 2), depicting that divalent vaccine has the potential to exhibit synergy
among its individual components and elevate the immune response against virulent Brucella abortus
544 challenge. During bacterial infection, Th2-mediated immune response is characterized by synthesis
and increase in the level of IgG1 antibodies [45,46] whereas Th1 immune response is represented by
levels of IgG2a antibody along with IFN-γ cytokine levels. The IgG subclass (IgG1, IgG2a and IgG2b)
detection in Omp25+L7/L12 immunized mice exhibited that IgG1 levels were significantly higher as
compared to IgG2a levels, predicting a more prominent Th2 immune response in case of anti-Omp25
and anti-L7/L12 antibodies (Figure 3). Although individual vaccinated group generated antibodies
specifically to single antigen immunized whereas divalent vaccine candidate resulted in generation
of antibodies against both antigens, rOmp25 and rL7/L12. Further, immunization with alum as an
adjuvant has also been suggested to enhance antibody response in mice [43,47]. It helps in enhancement
of antigen uptake and presentation to antigen-presenting cells, which results in promotion of Th2
immune responses [47,48]. Therefore, it is possible that alum has helped to increase antibody titer
and elevate the humoral immune response in divalent vaccine immunized mice [49]. The analysis of
protective efficacy in different mice groups after infection with virulent Brucella abortus 544 showed
that Omp25+L7/L12 immunized mice exhibited a significant increase in log10 protection (1.98) as
compared to the control (i.e. alum immunized mice) at 28 days after challenge (p value < 0.001; Table 1).
This specifies that Omp25+L7/L12 immunized mice were capable of eliminating pathogenic B. abortus
544 compared to the control group. On comparing log10 units of protection at 28 days after challenge
in individual protein immunized mice, rOmp25 (1.46) and rL7/12 (1.75) with alum as the adjuvant,
it was observed that Omp25+L7/L12 immunized mice showed a superior level of protection against B.
abortus 544 infection, however S19 exhibited the maximum.
It is noteworthy that although B. abortus recombinant subunit vaccines show very promising
results in mice models, the immune responses recognized in mice models may not reflect the protection
achieved in natural hosts such as cattle after immunization [11]. Therefore, further studies determining
protective efficacy in other animal models such as rats, guinea pigs, and monkeys are also encouraged
before proceeding towards cattle administration [50]. Recombinant vaccines also need multiple booster
administrations along with adjuvants and a combination of several antigens, which makes them
economically unsuitable for cattle immunization [51]. Hence, there is a need to decrease the production
cost, search for effective and affordable adjuvants, and reduce the expense of recombinant protein
purification in order to make these vaccines economical for mass administration.
In a nutshell, this preliminary study shows that the combination of rOmp25 and rL7/L12 elicited
steady immune responses against both antigens in mice. Further, when mice were immunized with the
Omp25+L7/L12 vaccine candidate, a significant reduction in B. abortus 544 load in mice spleens was
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observed, implying the use of divalent vaccine (Omp25+L7/L12) as an improved vaccine candidate
against brucellosis. Nevertheless, this study illustrates the potential of a divalent vaccine in providing
host immunity and protection against B. abortus challenge, suggesting the use of a divalent recombinant
vaccine candidate as an advanced approach in the future against brucellosis.
4. Materials and Methods
4.1. Plasmids and Bacterial Strains
E. coli DH5α was used for propagation of recombinant plasmids. E. coli BL21 (DE3) and C43 strains
were used for expression of rL7/L12 and rOmp25 proteins, respectively. E. coli strains were cultured
using Luria–Bertani (LB) medium. Kanamycin was added to the medium at a final concentration of
50 µg/mL. B. abortus 544 and S19 strains were obtained from the Indian Veterinary Research Institute,
Bareilly, India. Brucella abortus 544 was cultured in tryptic soy medium. Experiments involving
B. abortus 544 and S19 strains were performed in a biosafety Level 3 laboratory at Jawaharlal Nehru
University (JNU), Delhi, India.
4.2. Expression and Purification of Recombinant Proteins
For formulation of the divalent vaccine, Omp25 and L7/L12 antigens of Brucella abortus were
PCR amplified using gene specific primers and cloned in pET28(a) vector (Table 2). The expression
of proteins was done in E. coli. To purify rOmp25, recombinants were grown in terrific broth until
OD600 ~ 0.5–0.6, and then induction was done using 1 mM IPTG for 5 h at 37 ◦ C. Further purification
of rOmp25 was done from the insoluble inclusion bodies fraction, using the urea-denaturing method
and on-column refolding [20]. To purify rL7/L12, recombinants were grown in LB medium containing
kanamycin to OD600 ~ 0.7–0.8 followed by induction using 1 mM IPTG for 5 h at 37 ◦ C. Both the
proteins were affinity purified using immobilized nickel-nitrilotriacetic acid (Ni-NTA) agarose columns
equilibrated in PB buffer (100 mM potassium phosphate buffer, pH 8.0) and eluted using 100–500 mM
imidazole in PB. Purified proteins were analyzed by SDS-PAGE for content and purity. The dialysis of
purified proteins was done against phosphate buffer saline (pH 7.4).
Table 2. Description of strains used in this study.
S. No.

Protein Name

Strain Used for Purification of Protein

Reference

1.

rOmp25

omp25 gene was cloned in pET28a at
BamHI and SalI sites and expressed in
E. coli C43 cells.

Goel et al. 2012 [20]

2.

rL7/L12

L7/L12 ribosomal gene was cloned in
pET28a at NcoI and XhoI sites and
expressed in E. coli BL21(DE3) cells.

Singh et al. 2015 [1]

4.3. Immunoblotting
For immunoblotting, the recombinant proteins were resolved by 12% SDS-PAGE followed by
electroblotting onto nitrocellulose membrane. The membrane was further blocked using 3% BSA
followed by incubation with anti-Omp25+L7/L12 antibody (1:5000 dilution, raised in mice) for 1 h.
After subsequent washing, binding specificity was checked using AP-conjugated goat anti-mouse IgG
antibody (Catalog no. sc-2047, Santa Cruz Biotechnology, USA) [52–54].
4.4. Immunization of Respective Proteins in Mice
Four to six week old female BALB/c mice (inbred) were obtained from the National Centre for
Laboratory Animal Sciences, Hyderabad, India. Recommendations from the Institutional Animal Ethics
and Biosafety Committee were regularly followed during mouse experiments. In brief, mice were
caged under sterile conditions in micro-isolators, fed with pathogen-free food and water ad libitum
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during consecutive immunizations. Once infected with B. abortus 544, mice were maintained at the
BSL-3 animal facility of JNU for evaluation of protective efficacy.
For immunization of rL7/L12 and rOmp25, the optimized dose of each antigen was considered
as mentioned in earlier reports [1,20]. Briefly, mice were grouped and immunized through the
intraperitoneal route, either with Omp25 (30 µg) or L7/L12 (40 µg) alone or in combination as a divalent
vaccine candidate with alum as an adjuvant. Two boosters were administered at regular intervals of
2 weeks, and 1X PBS with alum and B. abortus S19 immunized mice groups were taken as controls.
For prime immunization and subsequent booster immunization, 100 µl emulsion of the required
antigen and alum in 1X PBS was injected in each mouse. The blood was collected from each mouse
on day 0, 14, 28, and 42 from tail veins and sera was extracted through centrifugation at 15,600 g for
20 min, followed by storage at −80 ◦ C for further analysis.
4.5. Elucidation of End-Point Antibody Titer
An enzyme-linked immunosorbent assay (ELISA) was used to analyze serum antibody titer.
In brief, 96-well microtiter plates (NuncMaxiSorp) were coated overnight with 500 ng/well of capture
antigen (rOmp25 or rL7/L12) in PBS at 4 ◦ C. The plates were washed three times using PBST (PBS with
0.1% tween 20) followed by blocking using 2% BSA in PBS for 2 h at 37 ◦ C. The antibody titer in the
sera of respective antigen immunized mice along with the divalent vaccine immunized mouse group
was assessed by priming dilutions of the same, in triplicates, at 37 ◦ C for 1 h. Washing of the plates
was done using PBST followed by addition of horseradish peroxidase (HRP)-conjugated anti-mouse
secondary antibodies (Catalog no. sc-2005, Santa Cruz Biotechnology, USA) at 1:10,000 dilution for
1 h at 37 ◦ C [53,54]. The plates were further incubated with OptEIA TMB substrate (BD Biosciences,
USA) for calorimetric assay and the reaction was stopped using 1N HCl. Absorbance of the plate
was measured at 450 nm through Tecan’s Sunrise absorbance microplate reader. End point titer was
evaluated as the reciprocal of highest dilution giving absorbance greater than the threshold value.
Threshold value was calculated as the mean of absorbance plus three times standard deviation of
1:1000 dilution of the control group (PBS + alum).
4.6. Analysis of IgG Isotypes in Immunized Mice
The IgG isotypes (IgG1, IgG2a and IgG2b) were detected in immunized mice using ELISA as
described above. For secondary antibodies, anti-mouse IgG1-HRP (Catalog no. sc-2060), anti-mouse
IgG2a-HRP (Catalog no. sc-2061) and anti-mouse IgG2b-HRP conjugated antibodies (Catalog no.
sc-2062) (raised in goat; Santa Cruz Biotechnology, USA) were used and absorbance at 450 nm was
measured [53].
4.7. Evaluation of Protective Efficacy of Vaccine Candidate
Two weeks after the final booster immunization (day 42), mice groups immunized with PBS,
rOmp25, rL7/L12, and divalent vaccine candidate (rOmp25+rL7/L12) were challenged with 2 × 105
cells of B. abortus 544 through the intraperitoneal route. B.abortus S19 was injected on day 0 in respective
group, and challenge was done after 21 days with 2 × 105 cells of virulent B. abortus 544. After 4 weeks
of infection, mice from each group were euthanized through cervical dislocation. Their spleen was
extracted under sterile conditions and finally homogenized in PBS using probe homogenizer. For CFU
count, various dilutions of the spleen homogenate were prepared and plated on tryptic soya agar
followed by incubation at 37 ◦ C for 48 h in the presence of 5% CO2 . Total splenic load was calculated
and represented as Log10 CFU mean ± standard deviation (SD). Log10 units of protection were
determined by calculating the difference between the log10 CFU of PBS injected group (control) and
vaccinated group.
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4.8. Statistical Analysis
The results are represented as mean ± SD and are reported as data of three different sets of
experiments. The statistical significance in antibody titer was calculated using two-tailed Student’s
t-test. (* represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001, **** represents P < 0.0001).
Ethical statement: All mice experiments were performed while abiding by the rules of Institutional
Animal Ethics Committee (IAEC), Jawaharlal Nehru University, New Delhi, India guidelines.
All experiments involving virulent Brucella abortus 544 and Brucella abortus S19 strain have been
performed in Biosafety level-3 (BSL-3) facility.
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